Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
18.03. | Prenetics Global Limited: Prenetics' IM8 Health Expands Scientific Advisory Board, Reinforcing Commitment to Set New Standards in Supplements Market | 2 | GlobeNewswire (USA) | ||
05.03. | Prenetics Global reports Q4 results | 1 | Seeking Alpha | ||
05.03. | Prenetics Global Limited: Prenetics Announces Fourth Quarter and Full Year 2024 Financial Results, Provides 2025 Guidance | 121 | GlobeNewswire (Europe) | Revenue grew 93.5% to $10.5 million in the fourth quarter and 40.9% year-over-year to $30.6 million in 2024 Cash and short-term assets of $84.8 million as of December 31, 2024 Provides first... ► Artikel lesen | |
05.03. | Prenetics Global Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
11.02. | Prenetics Global Limited: Nasdaq-Listed Prenetics Announces Genomics-Based Partnership with Humanity Protocol and Launches Crypto Strategic Reserve | 1 | GlobeNewswire (USA) | ||
15.01. | Prenetics Global Limited: Prenetics' IM8 Achieves Prestigious NSF Certified for Sport for Daily Ultimate Essentials | 1 | GlobeNewswire (USA) | ||
PRENETICS GLOBAL Aktie jetzt für 0€ handeln | |||||
13.12.24 | Prenetics Global Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
05.12.24 | Prenetics Global Limited: Prenetics' IM8 and University of Oxford Begin Groundbreaking Space Experiment to Study Accelerated Aging and Longevity on the ISS with SpaceX, Supported by Space Applications Services | 1 | GlobeNewswire (USA) | ||
27.11.24 | Prenetics Global Q3 Loss Narrows On Surge In Revenue | - | RTTNews | ||
27.11.24 | Prenetics Global: Q3 Earnings Insights | 1 | Benzinga.com | ||
27.11.24 | Prenetics Global Limited: Prenetics Announces Third Quarter 2024 Financial Results | 381 | GlobeNewswire (Europe) | Revenue Grew 59.4% to $7.8 million from Prior Year and 30.9% Sequentially Officially Launched IM8Health.com, a new premium supplements brand Tencent Invests $30 million in Insighta's Early Cancer... ► Artikel lesen | |
27.11.24 | Prenetics Global Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
18.11.24 | Prenetics Global Limited: Nasdaq-Listed Prenetics and David Beckham Officially Launch IM8 Health | 2 | GlobeNewswire (USA) | ||
07.10.24 | Prenetics Global Limited: Prenetics Announces Second Quarter 2024 Financial Results | 472 | GlobeNewswire (Europe) | Cost Optimization Boosted Gross Margin by 21.7% YoY in H1 2024Enters U.S. Health Market in October with IM8, a New Health and Wellness BrandRe-affirms Revenue Target to Exceed US$33 million for FY... ► Artikel lesen | |
11.07.24 | Prenetics Global Limited: Prenetics, NASDAQ Health Sciences Company, Partners with David Beckham | 477 | GlobeNewswire (Europe) | Beckham becomes a strategic investor in PreneticsBeckham and Prenetics are co-founding partners for IM8, a new health and wellness brand LOS ANGELES, July 11, 2024 (GLOBE NEWSWIRE) -- Prenetics... ► Artikel lesen | |
18.06.24 | Prenetics Global Limited: Prenetics Announces First Quarter 2024 Financial Results | 238 | GlobeNewswire (Europe) | First Quarter Revenue Increased 30.2% and Gross Profit Increased 159.8% from Prior Year Quarter Confirms Strategic Pivot Targeting the U.S. Consumer Healthcare Market Reaffirms 2024 Revenue Range... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QUANTUM-SI | 1,195 | +2,58 % | Quantum-Si Incorporated: Quantum-Si Showcases Advances in Multiomics at the Festival of Genomics UK | Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company, announces its participation in the upcoming Festival of Genomics UK, taking place on... ► Artikel lesen | |
SCILEX | 4,010 | -2,08 % | Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April ... | ||
EVOTEC | 7,320 | +1,41 % | DAX stabil, Gold stark: EZB-Zinsentscheid, Siemens Energy, Sartorius, Evotec, TSMC, Netflix ... | Der DAX hat sich am Mittwoch im Tagesverlauf stabilisieren können. Aus dem Handel ging er mit einem Minus von 0,5 Prozent auf 21.151 Zähler. Auch zum Start in den Donnerstag wird der deutsche Leitindex... ► Artikel lesen | |
TEMPUS AI | 51,04 | +2,97 % | Gemeinsam gegen Krebs: Tempus AI, AstraZeneca und Pathos AI entwickeln KI-Modell | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat heute bekannt gegeben, zusammen mit AstraZeneca und Pathos AI ein Foundation-Modell im Bereich der Onkologie zu entwickeln.... ► Artikel lesen | |
QIAGEN | 37,515 | -0,08 % | UBS stuft QIAGEN NV auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Qiagen bei einem Kursziel von 48 US-Dollar auf "Neutral" belassen. Die Ziele seien bestätigt worden, nähere Details seien... ► Artikel lesen | |
BIONTECH | 102,60 | +1,18 % | BioNTech-Aktie: Ein schnelles Ende! | News von Trading-Treff.de BioNTech schafft es derzeit einfach nicht, die negativen Stimmungen am Markt zu besiegen. Die Aktie verlor am Donnerstag rund 1,6 %. Damit ist der Wert wieder auf dem Weg in... ► Artikel lesen | |
MINERALYS THERAPEUTICS | 13,530 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM) | ||
TARSUS PHARMACEUTICALS | 49,990 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 ... | ||
NURIX THERAPEUTICS | 11,640 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions | Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025 GS-6791/NX-0479 has potential clinical... ► Artikel lesen | |
CG ONCOLOGY | 20,720 | 0,00 % | CG Oncology Inc.: CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates | - Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated... ► Artikel lesen | |
ADMA BIOLOGICS | 22,200 | +2,07 % | ADMA Biologics, Inc.: ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA(1)... ► Artikel lesen | |
BICARA THERAPEUTICS | 15,480 | 0,00 % | Bicara wird aktualisierte Studiendaten auf ASCO-Tagung präsentieren | ||
HARMONY BIOSCIENCES | 28,910 | 0,00 % | JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play? | ||
RECURSION PHARMACEUTICALS | 5,660 | +1,62 % | Recursion Pharmaceuticals: Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025 | ||
PRAXIS PRECISION MEDICINES | 36,590 | 0,00 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen |